PharmaShots Weekly Snapshots (March 03, 2025

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars, Animal Health & DigiHealth. Check out our full report below:

GSK Presents Pooled Analysis from P-III (ANCHOR-1 & 2) Trial of Depemokimab for CRSwNP at AAAAI/WAO Joint Congress 2025

Read More: GSK

Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study Evaluating Enhertu in HER2+ Metastatic Gastric Cancer Patients

Read More: Daiichi Sankyo

Contineum Therapeutics Initiates Patient Dosing in P-Ib Study to Evaluate PIPE-791 in Chronic Pain

Read More: Contineum Therapeutics

ITM Reports Topline Data from P-III (COMPETE) Trial of ITM-11 at the ENETS 2025 Conference

Read More: ITM

HUTCHMED Reports Enrollment Completion in P-II Trial of Fanregratinib for Intrahepatic Cholangiocarcinoma in China

Read More: HUTCHMED

Tris Pharma Reports P-III Clinical Data of Cebranopadol to Treat Moderate-to-Severe Acute Pain

Read More: Tris Pharma

AstraZeneca Reports P-III (MATTERHORN) Trial Data of Imfinzi as Perioperative Therapy for Stage II-IVA G/GEJ

Read More: AstraZeneca

Krystal Biotech’s Vyjuvek (beremagene geperpavec) Receives the CHMP’s Positive Opinion for Dystrophic Epidermolysis Bullosa (DEB)

Read More: Krystal Biotech

The CHMP Recommends Conditional Approval of Regeneron’s Linvoseltamab to Treat R/R Multiple Myeloma (MM)

Read More: Regeneron

Bavarian Nordic Reports the EC’s Approval of Vimkunya to Prevent Chikungunya

Read More: Bavarian Nordic

Johnson & Johnson’s Darzalex (daratumumab) Receives the CHMP’s Positive Opinion for Multiple Myeloma

Read More: J&J

The US FDA Accepts GSK’s Depemokimab Review Application for Asthma with Type 2 Inflammation and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Read More: GSK

BeiGene Reports the US FDA approval for Tevimbra + CT as a 1L Treatment of Advanced ESCC

Read More: BeiGene

Genentech Reports the FDA's sBLA Acceptance for Gazyva to Treat Lupus Nephritis

Read More: Genentech

Bioheng Therapeutics Secures the FDA Clearance of IND Application for CTD402 in T-ALL/LBL

Read More: Bioheng Therapeutics

ARS Pharmaceuticals’ neffy 1mg Secures the US FDA’s Approval to Treat Type I Allergic Reactions in Children

Read More: ARS Pharmaceuticals

Neurotech Pharmaceuticals Reports the US FDA Approval for Encelto to treat Macular Telangiectasia Type 2

Read More: Neurotech Pharmaceuticals

Magnet Biomedicine Partners with Eli Lilly to Advance Molecular Glue Therapeutics in Oncology

Read More: Magnet Biomedicine and Eli Lilly

AbbVie Enters into a Global License Agreement with Gubra to Develop & Commercialize GUB014295 to Treat Obesity

Read More: AbbVie and Gubra

KYORIN and Novartis Sign a $832.5M Global License Agreement for KRP-M223

Read More: KYORIN and Novartis

Astellas to Establish Joint Venture with YASKAWA for Cell Therapy Manufacturing

Read More: Astellas and YASKAWA

Biocon Biologics Partners with Civica to extend access of Insulin Aspart in the US

Read More: Biocon Biologics and Civica

Inspira Technologies Reports Positive Results from Clinical Study of HYLA Blood Sensor

Read More: Inspira Technologies

Johnson & Johnson MedTech Launches Shockwave Javelin Peripheral IVL Catheter in the US

Read More: J&J

BridgeBio Oncology Therapeutics (BBOT) Enters into Business Combination Agreement with Helix Acquisition Corp. II to Develop RAS and PI3Kα-Targeting Drugs

Boston Scientific Enters into a Definitive Agreement to Acquire SoniVie for $600M

Read More: Boston Scientific and SoniVie

Jazz Pharmaceuticals to Acquire Chimerix for ~$935M

Read More: Jazz Pharmaceuticals and Chimerix